OFEV by Boehringer Ingelheim
08 Palbociclib by Pfizer
Most Promising Drugs in 2015
09
OFEV by Boehringer Ingelheim
OFEV ( nintedanib ) by Boehringer Ingelheim has been approved by the FDA for the treatment of idiopathic pulmonary fibrosis ( IPF ). Prior to the approval , there were no FDA-approved treatments for IPF . In clinical trials , the drug reduced the annual decline in lung function by approximately 50 percent .
www . boehringer-ingelheim . com
08 Palbociclib by Pfizer
The experimental breast cancer drug by Pfizer ( NYSE : PFE ) significantly delayed progression of symptoms in a mid-stage trial . The trial tested the pill in postmenopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body . A secondary goal of the study is to determine whether palbociclib can prolong overall survival . Pfizer recently announced the completion of submission of a New Drug Application to the FDA .
www . pfizer . com
25